Dose-response Relationship in Cyclophosphamide-treated B-cell Lymphoma Xenografts Monitored with [18F]FDG PET

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2010 May 13

PMID 20461370

Citations 12

Authors

Lieselot Brepoels

Marijke De Saint-Hubert

Sigrid Stroobants

Gregor Verhoef

Jan Balzarini

Luc Mortelmans

Felix M Mottaghy

Affiliations

Soon will be listed here.

Abstract

Purpose: Although [(18)F]FDG PET can measure therapy response sooner and more accurately than morphological imaging techniques, there is still some debate as to whether [(18)F]FDG uptake really reflects changes in the viable cell fraction. In this study changes in [(18)F]FDG uptake were investigated in a lymphoma model at several time-points after treatment and with different doses of chemotherapy. Data were analysed in terms of several parameters.

Methods: SCID mice were subcutaneously inoculated with 5x10(6) Daudi cells in the right thigh. One group was not treated (control group). The other groups received cyclophosphamide 75 mg/kg (low-dose group), 125 mg/kg (medium-dose group) and 175 mg/kg (high-dose group) on day 0. Sequential [(18)F]FDG small-animal PET (microPET) scans were performed on days 0, 2, 6, 9, 13 and 16 after treatment. The mean and maximum standardized uptake value (SUV(mean) and SUV(max)), metabolic tumour volume (Vol(metab)) and total lesion glycolysis (TLG) were calculated.

Results: A significant decrease in [(18)F]FDG uptake was observed on day 2 in the medium-dose and high-dose groups and on day 6 in the low-dose group, all preceding morphological changes. SUV(mean) and SUV(max) formed a plateau from day 6 to day 9, corresponding to the known influx of inflammatory cells. No obvious plateau was observed with TLG which was found to be the most sensitive parameter clearly differentiating the low-dose group from the medium- and high-dose groups early after therapy.

Conclusion: [(18)F]FDG uptake was able to reflect the dose-response relationship for cyclophosphamide. TLG was the best parameter for dose-related response assessment in this tumour model.

Citing Articles

Early evaluation of tumor response to Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?.

Kitajima K, Okada M, Kashiwagi T, Yoshihara K, Tokugawa T, Sawada A Eur Radiol. 2019; 29(7):3935-3944.

PMID: 30899979 DOI: 10.1007/s00330-019-06134-7.

Evaluation of planar bioluminescence imaging and microPET/CT for therapy monitoring in a mouse model of pigmented metastatic melanoma.

Pasquereau-Kotula E, Hosten B, Hontonnou F, Vignal N, Antoni F, Poyet J Am J Nucl Med Mol Imaging. 2019; 8(6):397-406.

PMID: 30697459 PMC: 6334212.

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.

Yapp D, Wong M, Kyle A, Valdez S, Tso J, Yung A Angiogenesis. 2016; 19(2):229-44.

PMID: 26961182 PMC: 4819514. DOI: 10.1007/s10456-016-9503-z.

Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound.

Chen Y, Han F, Cao L, Li C, Wang J, Li Q BMC Cancer. 2015; 15:136.

PMID: 25884471 PMC: 4381667. DOI: 10.1186/s12885-015-1170-8.

Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease.

Cheng G, Kwee T, Basu S, Alavi A Eur J Nucl Med Mol Imaging. 2013; 40(8):1141-5.

PMID: 23695838 DOI: 10.1007/s00259-013-2459-y.

References

Kostakoglu L, Agress Jr H, Goldsmith S . Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003; 23(2):315-40; quiz 533. DOI: 10.1148/rg.232025705. View

Jensen M, Jorgensen J, Binderup T, Kjaer A . Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging. 2008; 8:16. PMC: 2575188. DOI: 10.1186/1471-2342-8-16. View

Tomayko M, Reynolds C . Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989; 24(3):148-54. DOI: 10.1007/BF00300234. View

Aide N, Poulain L, Briand M, Dutoit S, Allouche S, Labiche A . Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging. 2008; 36(3):396-405. DOI: 10.1007/s00259-008-0984-x. View

Euhus D, Hudd C, LaRegina M, Johnson F . Tumor measurement in the nude mouse. J Surg Oncol. 1986; 31(4):229-34. DOI: 10.1002/jso.2930310402. View

Zhuang H, Cortes-Blanco A, Pourdehnad M, Adam L, Yamamoto A, Martinez-Lazaro R . Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?. Nucl Med Commun. 2001; 22(10):1123-8. DOI: 10.1097/00006231-200110000-00011. View

Zinzani P, Stefoni V, Tani M, Fanti S, Musuraca G, Castellucci P . Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009; 27(11):1781-7. DOI: 10.1200/JCO.2008.16.1513. View

Juweid M, Cheson B . Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507. DOI: 10.1056/NEJMra050276. View

Spaepen K, Stroobants S, Dupont P, Bormans G, Balzarini J, Verhoef G . [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction?. Eur J Nucl Med Mol Imaging. 2003; 30(5):682-8. DOI: 10.1007/s00259-003-1120-6. View

10.

Brepoels L, Stroobants S, Vandenberghe P, Spaepen K, Dupont P, Nuyts J . Effect of corticosteroids on 18F-FDG uptake in tumor lesions after chemotherapy. J Nucl Med. 2007; 48(3):390-7. View

11.

de Geus-Oei L, van der Heijden H, Visser E, Hermsen R, van Hoorn B, Timmer-Bonte J . Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. J Nucl Med. 2007; 48(10):1592-8. DOI: 10.2967/jnumed.107.043414. View

12.

Lorenzen M, Wedegartner U, Weber C, Petersen J, Adam G, Lorenzen J . [Clinical relevance of multislice CT of the spine after osteosynthesis]. Rofo. 2005; 177(11):1540-4. DOI: 10.1055/s-2005-858555. View

13.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J . Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria. Leuk Lymphoma. 2007; 48(8):1522-30. DOI: 10.1080/10428190701474365. View

14.

Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T . Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002; 13(9):1356-63. DOI: 10.1093/annonc/mdf256. View

15.

Weber W, Petersen V, Schmidt B, Tyndale-Hines L, Link T, Peschel C . Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol. 2003; 21(14):2651-7. DOI: 10.1200/JCO.2003.12.004. View

16.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T . Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 33(11):1972-80. View

17.

Leyton J, Latigo J, Perumal M, Dhaliwal H, He Q, Aboagye E . Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005; 65(10):4202-10. DOI: 10.1158/0008-5472.CAN-04-4008. View

18.

Weber W . Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005; 46(6):983-95. View

19.

Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rube C . Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. J Nucl Med. 2005; 46(8):1342-8. View

20.

Brepoels L, Stroobants S, De Wever W, Spaepen K, Vandenberghe P, Thomas J . Hodgkin lymphoma: Response assessment by revised International Workshop Criteria. Leuk Lymphoma. 2007; 48(8):1539-47. DOI: 10.1080/10428190701422414. View